Article Text

Download PDFPDF
EP864 BRCA screening and burden of treatment among patients receiving active therapy for ovarian cancer
  1. J Hall1,
  2. M Monberg2,
  3. R Moon1,
  4. K McLaurin3 and
  5. T Dalvi3
  1. 1Adelphi Real World, Manchester, UK
  2. 2Merck Sharp and Dohme Corp., a Subsidiary of Merck and Co., Inc., Kenilworth, NJ
  3. 3AstraZeneca, Gaithersburg, MD, USA


Introduction/Background This analysis quantifies the burden among ovarian cancer (OC) patients within 4 years of diagnosis who received chemotherapy (chemo) only as 1L treatment.

Methodology This chart review and cross-sectional study included advanced OC patients who received chemo at 1L, had a diagnosis within 4 years, and received active treatment at the time of data collection. Between December 2017 and March 2018, 1159 detailed electronic record forms for patients meeting these criteria were provided by 340 oncologists/gynecologists from France, Germany, Italy, Spain, the UK and the US.

Results Mean age of all patients was 64 years. Most patients in the study were within 1 year of diagnosis (63%), followed by 1–2 years (22%), 2–3 years (10%) and 3–4 years (5%). BRCA screening rates increased with each line of therapy (42%, 47%, 62%, and 78% for 1L to 4L+). Of those tested, BRCA positivity rates were 20%, 27%, 29%, and 14% for 1L to 4L+. Regardless of the years since diagnosis, the time between lines of therapy decreased with progressive disease. Within the previous year, 33% of all patients had been hospitalized and 13% required a caregiver. Of patients on treatment at 3–4 years after diagnosis, 23% were receiving 3L and 10% were receiving a 4L or later line of therapy. Patients diagnosed 3–4 years ago had received an average of 14.2 months on treatment and a mean 24.1 months treatment-free regardless of line of therapy.

Conclusion In the real-world setting, a large proportion of advanced OC patients who receive chemo only at 1L are not BRCA tested. Those who receive chemo only as 1L treatment experience multiple lines of therapy within 4 years of diagnosis.

Disclosure M.J. Monberg is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. K. McLaurin and T. Dalvi are employees of AstraZeneca.

Abstract EP864 Table 1

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.